ВИКОРИСТАННЯ ФІТОТЕРАПІЇ В ЛІКУВАННІ ПСИХІЧНИХ ЗАХВОРЮВАНЬ НА ПРИКЛАДІ БІПОЛЯРНОГО РОЗЛАДУ

Tetiana Tiupova; Halina Tkaczenko; Natalia Kurhaluk

doi:10.58407/bht.1.23.6

Authors

Tetiana Tiupova Pomeranian University in Słupsk https://orcid.org/0000-0003-0929-8205
Halina Tkaczenko Pomeranian University in Słupsk https://orcid.org/0000-0003-3951-9005
Natalia Kurhaluk Pomeranian University in Słupsk https://orcid.org/0000-0002-4669-1092

DOI:

https://doi.org/10.58407/bht.1.23.6

Keywords:

bipolar disorder, phytotherapy, valerian (Valeriana officinalis L.), lemon balm (Melissa officinalis L.), passionflower (Passiflora incarnate L.), ginkgo biloba (Ginkgo biloba L.), St. John's wort (Hypericum perforatum L.), cannabinoids

Abstract

Purpose. Bipolar disorders are among the major health problems that exist worldwide. Bipolar disorder is a psychopathological disease manifested by sudden changes in mood and alternating bouts of mania and depression. They cause significant disturbance to the life quality and social functioning of the affected persons. Synthesized pharmaceuticals have been in use for decades to treat both mood disorders and depression, but despite their efficiency, their use is limited by numerous side effects. Studies to investigate the potential effects of medicinal plants acting on the nervous system and used to treat bipolar disorders are increasingly growing. This review highlights the antidepressant activities of herbals, with a particular focus on the treatment of bipolar disorders.

Methodology. This study is based on a literature review conducted through the search of relevant keywords in databases, i.e. Web of Science, Scopus, PubMed, Allied and Complementary Medicine, Embase, and Cochrane databases, and Google Scholar. Six plants were selected based on defined selection criteria for their that are used to reduce the symptoms of bipolar disorder.

Scientific novelty. In this review, we presented the antidepressant effects of 6 plant species, with a particular focus on the treatment of bipolar disorders. Emphasis is placed on the pharmacological properties and active substances of the listed medicinal plants (valerian, lemon balm, passionflower, ginkgo biloba, St. John's wort, kava, etc.).

Conclusions. Six plants were selected based on defined selection criteria for their that are used to reduce the symptoms of bipolar disorder. The detailed analysis of the research studies revealed that among the herbal preparations that are used to reduce the symptoms of bipolar disorder, it is possible to note valerian, lemon balm, passionflower, ginkgo, St. John's wort, kava, etc. This review, therefore, provides an overview of the work done on botanicals for bipolar disorders.

Downloads

Download data is not yet available.

References

Alves, J. S. F., Silva, A. M. D. S., da Silva, R. M., Tiago, P. R. F., de Carvalho, T. G., de Araújo Júnior, R. F., de Azevedo, E. P., Lopes, N. P., Ferreira, L. S., Gavioli, E. C., da Silva-Júnior, A. A., & Zucolotto, S. M. (2020). In Vivo Antidepressant Effect of Passiflora edulis f. flavicarpa into Cationic Nanoparticles: Improving Bioactivity and Safety. Pharmaceutics, 12(4), 383. https://doi.org/10.3390/pharmaceutics12040383.

Andreatini, R., Sartori, V. A., Seabra, M. L., & Leite, J. R. (2002). Effect of valepotriates (valerian extract) in generalized anxiety disorder: a randomized placebo-controlled pilot study. Phytotherapy research: PTR, 16(7), 650–654. https://doi.org/10.1002/ptr.1027.

Arjmand, S., Behzadi, M., Kohlmeier, K. A., Mazhari, S., Sabahi, A., & Shabani, M. (2019). Bipolar disorder and the endocannabinoid system. Acta neuropsychiatrica, 31(4), 193–201. https://doi.org/10.1017/neu.2019.21.

Ashton, C. H., Moore, P. B., Gallagher, P., & Young, A. H. (2005). Cannabinoids in bipolar affective disorder: a review and discussion of their therapeutic potential. Journal of psychopharmacology (Oxford, England), 19(3), 293–300. https://doi.org/10.1177/0269881105051541.

Ashton, H., & Young, A. H. (2003). GABA-ergic drugs: exit stage left, enter stage right. Journal of psychopharmacology (Oxford, England), 17(2), 174–178. https://doi.org/10.1177/0269881103017002004.

Aslanargun, P., Cuvas, O., Dikmen, B., Aslan, E., & Yuksel, M. U. (2012). Passiflora incarnata Linneaus as an anxiolytic before spinal anesthesia. Journal of anesthesia, 26(1), 39–44. https://doi.org/10.1007/s00540-011-1265-6.

Baldessarini, R. J., Leahy, L., Arcona, S., Gause, D., Zhang, W., & Hennen, J. (2007). Patterns of psychotropic drug prescription for U.S. patients with diagnoses of bipolar disorders. Psychiatric services (Washington, D.C.), 58(1), 85–91. https://doi.org/10.1176/ps.2007.58.1.85.

Baldwin, D. S., Montgomery, S. A., Nil, R., & Lader, M. (2007). Discontinuation symptoms in depression and anxiety disorders. The international journal of neuropsychopharmacology, 10(1), 73–84. https://doi.org/10.1017/S1461145705006358.

Barbosa, P. R., Valvassori, S. S., Bordignon, C. L., Jr, Kappel, V. D., Martins, M. R., Gavioli, E. C., Quevedo, J., & Reginatto, F. H. (2008). The aqueous extracts of Passiflora alata and Passiflora edulis reduce anxiety-related behaviors without affecting memory process in rats. Journal of medicinal food, 11(2), 282–288. https://doi.org/10.1089/jmf.2007.722.

Barnes, J., Anderson, L. A., & Phillipson, J. D. (2001). St John's wort (Hypericum perforatum L.): a review of its chemistry, pharmacology and clinical properties. The Journal of pharmacy and pharmacology, 53(5), 583–600. https://doi.org/10.1211/0022357011775910.

Basco M., & Rush A. (1995). Cognitive-Behavioural Treatment of Manic-Depressive Disoder. New York: Guilford Press.

Berk, M., Berk, L., Dodd, S., Cotton, S., Macneil, C., Daglas, R., Conus, P., Bechdolf, A., Moylan, S., & Malhi, G. S. (2014). Stage managing bipolar disorder. Bipolar disorders, 16(5), 471–477. https://doi.org/10.1111/bdi.12099.

Berk, M., Conus, P., Lucas, N., Hallam, K., Malhi, G. S., Dodd, S., Yatham, L. N., Yung, A., & McGorry, P. (2007). Setting the stage: from prodrome to treatment resistance in bipolar disorder. Bipolar disorders, 9(7), 671–678. https://doi.org/10.1111/j.1399-5618.2007.00484.x.

Berk, M., Hallam, K. T., & McGorry, P. D. (2007). The potential utility of a staging model as a course specifier: a bipolar disorder perspective. Journal of affective disorders, 100(1-3), 279–281. https://doi.org/10.1016/j.jad.2007.03.007.

Bian, T., Corral, P., Wang, Y., Botello, J., Kingston, R., Daniels, T., Salloum, R. G., Johnston, E., Huo, Z., Lu, J., Liu, A. C., & Xing, C. (2020). Kava as a Clinical Nutrient: Promises and Challenges. Nutrients, 12(10), 3044. https://doi.org/10.3390/nu12103044.

Birks, J., & Grimley Evans, J. (2009). Ginkgo biloba for cognitive impairment and dementia. The Cochrane database of systematic reviews, (1), CD003120. https://doi.org/10.1002/14651858.CD003120.pub3.

Black, N., Stockings, E., Campbell, G., Tran, L. T., Zagic, D., Hall, W. D., Farrell, M., & Degenhardt, L. (2019). Cannabinoids for the treatment of mental disorders and symptoms of mental disorders: a systematic review and meta-analysis. The Lancet Psychiatry, 6(12), 995–1010. https://doi.org/10.1016/S2215-0366(19)30401-8.

Blanco, C., Laje, G., Olfson, M., Marcus, S. C., & Pincus, H. A. (2002). Trends in the treatment of bipolar disorder by outpatient psychiatrists. The American journal of psychiatry, 159(6), 1005–1010. https://doi.org/10.1176/appi.ajp.159.6.1005.

Bobo W. V. (2014). The Diagnosis and Management of Bipolar I and II Disorders: Clinical Practice Update. Mayo Clinic proceedings, 92(10), 1532–1551. https://doi.org/10.1016/j.mayocp.2017.06.022.

Borgert, C. J., Borgert, S. A., & Findley, K. C. (2005). Synergism, antagonism, or additivity of dietary supplements: application of theory to case studies. Thrombosis research, 117(1-2), 123–151. https://doi.org/10.1016/j.thromres.2005.06.008.

Borrelli, F., & Izzo, A. A. (2009). Herb-drug interactions with St John's wort (Hypericum perforatum): an update on clinical observations. The AAPS journal, 11(4), 710–727. https://doi.org/10.1208/s12248-009-9146-8.

Brunette, M. F., Noordsy, D. L., Xie, H., & Drake, R. E. (2003). Benzodiazepine use and abuse among patients with severe mental illness and co-occurring substance use disorders. Psychiatric services (Washington, D.C.), 54(10), 1395–1401. https://doi.org/10.1176/appi.ps.54.10.1395.

Budde, M., Forstner, A. J., Adorjan, K., Schaupp, S. K., Nöthen, M. M., & Schulze, T. G. (2017). Genetische Grundlagen der bipolaren Störung [Genetics of bipolar disorder]. Der Nervenarzt, 88(7), 755–759. https://doi.org/10.1007/s00115-017-0336-9.

Butterweck V. (2003). Mechanism of action of St John's wort in depression: what is known? CNS drugs, 17(8), 539–562. https://doi.org/10.2165/00023210-200317080-00001.

Chen, P., , Hei, M., Kong, L., Liu, Y., Yang, Y., Mu, H., Zhang, X., Zhao, S., & Duan, J. (2019). One water-soluble polysaccharide from Ginkgo biloba leaves with antidepressant activities via modulation of the gut microbiome. Food & function, 10(12), 8161–8171. https://doi.org/10.1039/c9fo01178a.

Circosta, C., De Pasquale, R., Samperi, S., Pino, A., & Occhiuto, F. (2007). Biological and analytical characterization of two extracts from Valeriana officinalis. Journal of ethnopharmacology, 112(2), 361–367. https://doi.org/10.1016/j.jep.2007.03.021.

Clark, R. E., Xie, H., & Brunette, M. F. (2004). Benzodiazepine prescription practices and substance abuse in persons with severe mental illness. The Journal of clinical psychiatry, 65(2), 151–155. https://doi.org/10.4088/jcp.v65n0202.

Coulter D. (2007). Assessment of the risk of hepatotoxicity with kava products. Geneva: WHO Appointed Committee.

Cristino, L., Bisogno, T., & Di Marzo, V. (2020). Cannabinoids and the expanded endocannabinoid system in neurological disorders. Nature reviews. Neurology, 16(1), 9–29. https://doi.org/10.1038/s41582-019-0284-z.

Curran, G., & Ravindran, A. (2014). Lithium for bipolar disorder: a review of the recent literature. Expert review of neurotherapeutics, 14(9), 1079–1098. https://doi.org/10.1586/14737175.2014.947965.

da Fonseca, L. R., Rodrigues, R. A., Ramos, A. S., da Cruz, J. D., Ferreira, J. L. P., Silva, J. R. A., & Amaral, A. C. F. (2020). Herbal Medicinal Products from Passiflora for Anxiety: An Unexploited Potential. The Scientific World Journal, 2020, 6598434. https://doi.org/10.1155/2020/6598434.

Davidson, J. R., & Connor, K. M. (2001). St. John's wort in generalized anxiety disorder: three case reports. Journal of clinical psychopharmacology, 21(6), 635–636. https://doi.org/10.1097/00004714-200112000-00026.

Devinsky, O., Cross, J. H., Laux, L., Marsh, E., Miller, I., Nabbout, R., Scheffer, I. E., Thiele, E. A., Wright, S., & Cannabidiol in Dravet Syndrome Study Group. (2017). Trial of Cannabidiol for Drug-Resistant Seizures in the Dravet Syndrome. The New England journal of medicine, 376(21), 2011–2020. https://doi.org/10.1056/NEJMoa1611618.

Devinsky, O., Patel, A. D., Cross, J. H., Villanueva, V., Wirrell, E. C., Privitera, M., Greenwood, S. M., Roberts, C., Checketts, D., VanLandingham, K. E., Zuberi, S. M., & GWPCARE3 Study Group. (2018). Effect of Cannabidiol on Drop Seizures in the Lennox-Gastaut Syndrome. The New England journal of medicine, 378(20), 1888–1897. https://doi.org/10.1056/NEJMoa1714631.

Dodd, S., & Berk, M. (2004). Predictors of antidepressant response: A selective review. International journal of psychiatry in clinical practice, 8(2), 91–100. https://doi.org/10.1080/13651500410005423.

Eisvand, F., Razavi, B. M., & Hosseinzadeh, H. (2020). The effects of Ginkgo biloba on metabolic syndrome: A review. Phytotherapy research: PTR, 34(8), 1798–1811. https://doi.org/10.1002/ptr.6646.

El-Mallakh R. S. (2007). Medication adherence and the use of long-acting antipsychotics in bipolar disorder. Journal of psychiatric practice, 13(2), 79–85. https://doi.org/10.1097/01.pra.0000265764.87376.02.

Estroff, T. W., Dackis, C. A., Gold, M. S., & Pottash, A. L. (1985). Drug abuse and bipolar disorders. International journal of psychiatry in medicine, 15(1), 37–40. https://doi.org/10.2190/6d4m-j23x-l21c-tp21.

Fahami, F., Asali, Z., Aslani, A., & Fathizadeh, N. (2010). A comparative study on the effects of Hypericum Perforatum and passion flower on the menopausal symptoms of women referring to Isfahan city health care centers. Iranian journal of nursing and midwifery research, 15(4), 202–207.

Falasca, M., & Maccarrone, M. (2021). Cannabinoids and Cancer. Cancers, 13(17), 4458. https://doi.org/10.3390/cancers13174458.

Filippini, G., Minozzi, S., Borrelli, F., Cinquini, M., & Dwan, K. (2022). Cannabis and cannabinoids for symptomatic treatment for people with multiple sclerosis. The Cochrane database of systematic reviews, 5(5), CD013444. https://doi.org/10.1002/14651858.CD013444.pub2.

Fraguas-Sánchez, A. I., & Torres-Suárez, A. I. (2018). Medical Use of Cannabinoids. Drugs, 78(16), 1665–1703. https://doi.org/10.1007/s40265-018-0996-1

Gao, K., Muzina, D., Gajwani, P., & Calabrese, J. R. (2006). Efficacy of typical and atypical antipsychotics for primary and comorbid anxiety symptoms or disorders: a review. The Journal of clinical psychiatry, 67(9), 1327–1340. https://doi.org/10.4088/jcp.v67n0902.

Geddes, J. R., Carney, S. M., Davies, C., Furukawa, T. A., Kupfer, D. J., Frank, E., & Goodwin, G. M. (2003). Relapse prevention with antidepressant drug treatment in depressive disorders: a systematic review. Lancet (London, England), 361(9358), 653–661. https://doi.org/10.1016/S0140-6736(03)12599-8.

Geddes, J., & Goodwin, G. (2001). Bipolar disorder: clinical uncertainty, evidence-based medicine and large-scale randomised trials. The British journal of psychiatry. Supplement, 41, s191–s194.

Ghaemi, S. N., Hsu, D. J., Thase, M. E., Wisniewski, S. R., Nierenberg, A. A., Miyahara, S., & Sachs, G. (2006). Pharmacological Treatment Patterns at Study Entry for the First 500 STEP-BD Participants. Psychiatric services (Washington, D.C.), 57(5), 660–665. https://doi.org/10.1176/ps.2006.57.5.660.

Ghazizadeh, J., Hamedeyazdan, S., Torbati, M., Farajdokht, F., Fakhari, A., Mahmoudi, J., Araj-Khodaei, M., & Sadigh-Eteghad, S. (2020). Melissa officinalis L. hydro-alcoholic extract inhibits anxiety and depression through prevention of central oxidative stress and apoptosis. Experimental physiology, 105(4), 707–720. https://doi.org/10.1113/EP088254.

Goodwin, G. M., & Consensus Group of the British Association for Psychopharmacology. (2003). Evidence-based guidelines for treating bipolar disorder: recommendations from the British Association for Psychopharmacology. Journal of psychopharmacology (Oxford, England), 17(2), 149–147. https://doi.org/10.1177/0269881103017002003.

Grinspoon, L., & Bakalar, J. B. (1998). The use of cannabis as a mood stabilizer in bipolar disorder: anecdotal evidence and the need for clinical research. Journal of psychoactive drugs, 30(2), 171–177. https://doi.org/10.1080/02791072.1998.10399687.

Gruber, A. J., Pope, H. G., Jr, & Brown, M. E. (1996). Do patients use marijuana as an antidepressant? Depression, 4(2), 77–80. https://doi.org/10.1002/(SICI)1522-7162(1996).

Hartley, D. E., Elsabagh, S., & File, S. E. (2004). Gincosan (a combination of Ginkgo biloba and Panax ginseng): the effects on mood and cognition of 6 and 12 weeks’ treatment in post-menopausal women. Nutritional neuroscience, 7(5-6), 325–333. https://doi.org/10.1080/10284150400015557.

Hattesohl, M., Feistel, B., Sievers, H., Lehnfeld, R., Hegger, M., & Winterhoff, H. (2008). Extracts of Valeriana officinalis L. s.l. show anxiolytic and antidepressant effects but neither sedative nor myorelaxant properties. Phytomedicine: international journal of phytotherapy and phytopharmacology, 15(1-2), 2–15. https://doi.org/10.1016/j.phymed.2007.11.027.

Huang, S. H., Duke, R. K., Chebib, M., Sasaki, K., Wada, K., & Johnston, G. A. (2004). Ginkgolides, diterpene trilactones of Ginkgo biloba, as antagonists at recombinant alpha1beta2gamma2L GABAA receptors. European journal of pharmacology, 494(2-3), 131–138. https://doi.org/10.1016/j.ejphar.2004.04.051.

Ihl, R., Tribanek, M., Bachinskaya, N., & GOTADAY Study Group. (2012). Efficacy tolerability of a once daily formulation of Ginkgo biloba extract EGb 761® in Alzheimer's disease and vascular dementia: results from a randomised controlled trial. Pharmacopsychiatry, 45(2), 41–46. https://doi.org/10.1055/s-0031-1291217.

Ising, M., & Holsboer, F. (2006). Genetics of stress response and stress-related disorders. Dialogues in clinical neuroscience, 8(4), 433–444. https://doi.org/10.31887/DCNS.2006.8.4/mising.

Izzo, A. A., & Ernst, E. (2009). Interactions between herbal medicines and prescribed drugs: an updated systematic review. Drugs, 69(13), 1777–1798. https://doi.org/10.2165/11317010-000000000-00000.

Jefferson J. W. (2005). Old versus new medications: how much should be taught? Academic psychiatry: the journal of the American Association of Directors of Psychiatric Residency Training and the Association for Academic Psychiatry, 29(2), 162–166. https://doi.org/10.1176/appi.ap.29.2.162.

Judd, L. L., Akiskal, H. S., Schettler, P. J., Endicott, J., Maser, J., Solomon, D. A., Leon, A. C., Rice, J. A., & Keller, M. B. (2002). The long-term natural history of the weekly symptomatic status of bipolar I disorder. Archives of general psychiatry, 59(6), 530–537. https://doi.org/10.1001/archpsyc.59.6.530.

Jussofie, A., Schmiz, A., & Hiemke, C. (1994). Kavapyrone enriched extract from Piper methysticum as modulator of the GABA binding site in different regions of rat brain. Psychopharmacology, 116(4), 469–474. https://doi.org/10.1007/BF02247480.

Karanti, A., Kardell, M., Joas, E., Runeson, B., Pålsson, E., & Landén, M. (2020). Characteristics of bipolar I and II disorder: A study of 8766 individuals. Bipolar disorders, 22(4), 392–400. https://doi.org/10.1111/bdi.12867.

Karege, F., Perret, G., Bondolfi, G., Schwald, M., Bertschy, G., & Aubry, J. M. (2002). Decreased serum brain-derived neurotrophic factor levels in major depressed patients. Psychiatry research, 109(2), 143–148. https://doi.org/10.1016/s0165-1781(02)00005-7.

Kassam, A., & Patten, S. B. (2006). Hypnotic use in a population-based sample of over thirty-five thousand interviewed Canadians. Population health metrics, 4, 15. https://doi.org/10.1186/1478-7954-4-15.

Kato, T., Kunugi, H., Nanko, S., & Kato, N. (2000). Association of bipolar disorder with the 5178 polymorphism in mitochondrial DNA. American journal of medical genetics, 96(2), 182–186.

Keck, P. E., Jr, Marcus, R., Tourkodimitris, S., Ali, M., Liebeskind, A., Saha, A., Ingenito, G., & Aripiprazole Study Group (2003). A placebo-controlled, double-blind study of the efficacy and safety of aripiprazole in patients with acute bipolar mania. The American journal of psychiatry, 160(9), 1651–1658. https://doi.org/10.1176/appi.ajp.160.9.1651.

Keck, P. E., Jr, Versiani, M., Potkin, S., West, S. A., Giller, E., Ice, K., & Ziprasidone in Mania Study Group. (2003). Ziprasidone in the treatment of acute bipolar mania: a three-week, placebo-controlled, double-blind, randomized trial. The American journal of psychiatry, 160(4), 741–748. https://doi.org/10.1176/appi.ajp.160.4.741.

Keck, P. E., McElroy, S. L., Strakowski, S. M., Balistreri, T. M., Kizer, D. I., & West, S. A. (1996). Factors associated with maintenance antipsychotic treatment of patients with bipolar disorder. The Journal of clinical psychiatry, 57(4), 147–151.

Kemp, D. E., Gilmer, W. S., Fleck, J., Straus, J. L., Dago, P. L., & Karaffa, M. (2007). Aripiprazole augmentation in treatment-resistant bipolar depression: early response and development of akathisia. Progress in neuro-psychopharmacology & biological psychiatry, 31(2), 574–577. https://doi.org/10.1016/j.pnpbp.2006.12.009.

Kennedy, D. O., Little, W., & Scholey, A. B. (2004). Attenuation of laboratory-induced stress in humans after acute administration of Melissa officinalis (Lemon Balm). Psychosomatic medicine, 66(4), 607–613. https://doi.org/10.1097/01.psy.0000132877.72833.71.

Kennedy, D. O., Little, W., Haskell, C. F., & Scholey, A. B. (2006). Anxiolytic effects of a combination of Melissa officinalis and Valeriana officinalis during laboratory induced stress. Phytotherapy research : PTR, 20(2), 96–102. https://doi.org/10.1002/ptr.1787.

Kennedy, D. O., Scholey, A. B., Tildesley, N. T., Perry, E. K., & Wesnes, K. A. (2002). Modulation of mood and cognitive performance following acute administration of Melissa officinalis (lemon balm). Pharmacology, biochemistry, and behavior, 72(4), 953–964. https://doi.org/10.1016/s0091-3057(02)00777-3.

Ketcha Wanda, G.J., Ngitedem, S.G., & Njamen, D. (2015). Botanicals for mood disorders with a focus on epilepsy. Epilepsy Behav., 52(Pt B), 319-28. doi: 10.1016/j.yebeh.2015.08.019.

Kieseppä, T., Partonen, T., Haukka, J., Kaprio, J., & Lönnqvist, J. (2004). High concordance of bipolar I disorder in a nationwide sample of twins. The American journal of psychiatry, 161(10), 1814–1821. https://doi.org/10.1176/ajp.161.10.1814.

Kobak, K. A., Taylor, L. V., Bystritsky, A., Kohlenberg, C. J., Greist, J. H., Tucker, P., Warner, G., Futterer, R., & Vapnik, T. (2005a). St John's wort versus placebo in obsessive-compulsive disorder: results from a double-blind study. International clinical psychopharmacology, 20(6), 299–304. https://doi.org/10.1097/00004850-200511000-00003.

Kobak, K. A., Taylor, L. V., Warner, G., & Futterer, R. (2005b). St. John's wort versus placebo in social phobia: results from a placebo-controlled pilot study. Journal of clinical psychopharmacology, 25(1), 51–58. https://doi.org/10.1097/01.jcp.0000150227.61501.00.

Kobak, K. A., Taylor, L.v, Futterer, R., & Warner, G. (2003). St. John's wort in generalized anxiety disorder: three more case reports. Journal of clinical psychopharmacology, 23(5), 531–532. https://doi.org/10.1097/01.jcp.0000088921.02635.13.

Kohnen, R., & Oswald, W.D. (1988). The effects of valerian, propranolol, and their combination on activation, performance, and mood of healthy volunteers under social stress conditions. Pharmacopsychiatry, 21(6), 447-448.

LaPorte, E., Sarris, J., Stough, C., & Scholey, A. (2011). Neurocognitive effects of kava (Piper methysticum): a systematic review. Human psychopharmacology, 26(2), 102–111. https://doi.org/10.1002/hup.1180.

Levine, J., Chengappa, K. N., Brar, J. S., Gershon, S., Yablonsky, E., Stapf, D., & Kupfer, D. J. (2000). Psychotropic drug prescription patterns among patients with bipolar I disorder. Bipolar disorders, 2(2), 120–130. https://doi.org/10.1034/j.1399-5618.2000.020205.x.

Licht R. W. (2012). Lithium: still a major option in the management of bipolar disorder. CNS neuroscience & therapeutics, 18(3), 219–226. https://doi.org/10.1111/j.1755-5949.2011.00260.x.

Lichtman, A. H., Lux, E. A., McQuade, R., Rossetti, S., Sanchez, R., Sun, W., Wright, S., Kornyeyeva, E., & Fallon, M. T. (2018). Results of a Double-Blind, Randomized, Placebo-Controlled Study of Nabiximols Oromucosal Spray as an Adjunctive Therapy in Advanced Cancer Patients with Chronic Uncontrolled Pain. Journal of pain and symptom management, 55(2), 179–188.e1. https://doi.org/10.1016/j.jpainsymman.2017.09.001.

Lin, P. H., Kuo, L. T., & Luh, H. T. (2021). The Roles of Neurotrophins in Traumatic Brain Injury. Life (Basel, Switzerland), 12(1), 26. https://doi.org/10.3390/life12010026.

Lin, S. C., Chen, C. C., Chen, Y. H., Chung, K. S., & Lin, C. H. (2011). Benzodiazepine prescription among patients with severe mental illness and co-occurring alcohol abuse/dependence in Taiwan. Human psychopharmacology, 26(3), 201–207. https://doi.org/10.1002/hup.1193.

Linde, K., Berner, M., Egger, M., & Mulrow, C. (2005). St John's wort for depression: meta-analysis of randomised controlled trials. The British journal of psychiatry : the journal of mental science, 186, 99–107. https://doi.org/10.1192/bjp.186.2.99.

Lloyd, A. J., Harrison, C. L., Ferrier, I. N., & Young, A. H. (2003). The pharmacological treatment of bipolar affective disorder: practice is improving but could still be better. Journal of psychopharmacology (Oxford, England), 17(2), 230–233. https://doi.org/10.1177/0269881103017002013.

Ludwig, B., & Dwivedi, Y. (2016). Dissecting bipolar disorder complexity through epigenomic approach. Molecular psychiatry, 21(11), 1490–1498. https://doi.org/10.1038/mp.2016.123.

Malva, J. O., Santos, S., & Macedo, T. (2004). Neuroprotective properties of Valeriana officinalis extracts. Neurotoxicity research, 6(2), 131–140. https://doi.org/10.1007/BF03033215.

Mangal, N., Erridge, S., Habib, N., Sadanandam, A., Reebye, V., & Sodergren, M. H. (2021). Cannabinoids in the landscape of cancer. Journal of cancer research and clinical oncology, 147(9), 2507–2534. https://doi.org/10.1007/s00432-021-03710-7.

Mansell, W., & Pedley, R. (2008). The ascent into mania: a review of psychological processes associated with the development of manic symptoms. Clinical psychology review, 28(3), 494–520. https://doi.org/10.1016/j.cpr.2007.07.010.

Marken, P. A., Stanislav, S. W., Lacombe, S., Pierce, C., Hornstra, R., & Sommi, R. W. (1992). Profile of a sample of subjects admitted to an acute care psychiatric facility with manic symptoms. Psychopharmacology bulletin, 28(2), 201–205.

McElroy, S. L., Suppes, T., Frye, M. A., Altshuler, L. L., Stanford, K., Martens, B., Leverich, G. S., Post, R. M., & Keck Jr., P. E. (2007). Open-label aripiprazole in the treatment of acute bipolar depression: a prospective pilot trial. Journal of affective disorders, 101(1-3), 275–281. https://doi.org/10.1016/j.jad.2006.11.025.

McGorry, P. D., Hickie, I. B., Yung, A. R., Pantelis, C., & Jackson, H. J. (2006). Clinical staging of psychiatric disorders: a heuristic framework for choosing earlier, safer and more effective interventions. The Australian and New Zealand journal of psychiatry, 40(8), 616–622. https://doi.org/10.1080/j.1440-1614.2006.01860.x.

Meehan, K., Zhang, F., David, S., Tohen, M., Janicak, P., Small, J., Koch, M., Rizk, R., Walker, D., Tran, P., & Breier, A. (2001). A double-blind, randomized comparison of the efficacy and safety of intramuscular injections of olanzapine, lorazepam, or placebo in treating acutely agitated patients diagnosed with bipolar mania. Journal of clinical psychopharmacology, 21(4), 389–397. https://doi.org/10.1097/00004714-200108000-00006.

Mei, N., Guo, X., Ren, Z., Kobayashi, D., Wada, K., & Guo, L. (2017). Review of Ginkgo biloba-induced toxicity, from experimental studies to human case reports. Journal of environmental science and health. Part C, Environmental carcinogenesis & ecotoxicology reviews, 35(1), 1–28. https://doi.org/10.1080/10590501.2016.1278298.

Meyer, T. D., Finucane, L., & Jordan, G. (2011). Is risk for mania associated with increased daydreaming as a form of mental imagery? Journal of affective disorders, 135(1-3), 380–383. https://doi.org/10.1016/j.jad.2011.06.002.

Miller, F. T., Busch, F., & Tanenbaum, J. H. (1989). Drug abuse in schizophrenia and bipolar disorder. The American journal of drug and alcohol abuse, 15(3), 291–295. https://doi.org/10.3109/00952998908993409.

Miroddi, M., Calapai, G., Navarra, M., Minciullo, P. L., & Gangemi, S. (2013). Passiflora incarnata L.: ethnopharmacology, clinical application, safety and evaluation of clinical trials. Journal of ethnopharmacology, 150(3), 791–804. https://doi.org/10.1016/j.jep.2013.09.047.

Mischoulon, D. (2008) Herbal remedies for anxiety and insomnia: Kava and valerian. In: Mischoulon D. and Rosenbaum J.F. (eds) Natural Medications for Psychiatric Disorders. Philadelphia, Pennsylvania: Lippincott Williams & Wilkins, pp. 119–139.

Mishra, A., Moore, P. B., & Hobbs, R. (2004). Does quetiapine have mood altering properties? Journal of psychopharmacology (Oxford, England), 18(2), 281–284. https://doi.org/10.1177/0269881104042635.

Mix, J. A., & Crews Jr., W. D. (2000). An examination of the efficacy of Ginkgo biloba extract EGb761 on the neuropsychologic functioning of cognitively intact older adults. Journal of alternative and complementary medicine (New York, N.Y.), 6(3), 219–229. https://doi.org/10.1089/acm.2000.6.219.

Mueser, K. T., Yarnold, P. R., & Bellack, A. S. (1992). Diagnostic and demographic correlates of substance abuse in schizophrenia and major affective disorder. Acta psychiatrica Scandinavica, 85(1), 48–55. https://doi.org/10.1111/j.1600-0447.1992.tb01441.x.

Müller, J. K., & Leweke, F. M. (2016). Bipolar disorder: clinical overview. Klinik bipolarer Erkrankungen. Medizinische Monatsschrift fur Pharmazeuten, 39(9), 363–369.

Müller, S. F., & Klement, S. (2006). A combination of valerian and lemon balm is effective in the treatment of restlessness and dyssomnia in children. Phytomedicine: international journal of phytotherapy and phytopharmacology, 13(6), 383–387. https://doi.org/10.1016/j.phymed.2006.01.013.

Ng, Q. X., Venkatanarayanan, N., & Ho, C. Y. (2017). Clinical use of Hypericum perforatum (St John's wort) in depression: A meta-analysis. Journal of affective disorders, 210, 211–221. https://doi.org/10.1016/j.jad.2016.12.048.

Ngan, A., & Conduit, R. (2011). A double-blind, placebo-controlled investigation of the effects of Passiflora incarnata (passionflower) herbal tea on subjective sleep quality. Phytotherapy research: PTR, 25(8), 1153–1159. https://doi.org/10.1002/ptr.3400.

Occhiuto, F., Pino, A., Palumbo, D. R., Samperi, S., De Pasquale, R., Sturlese, E., & Circosta, C. (2009). Relaxing effects of Valeriana officinalis extracts on isolated human non-pregnant uterine muscle. The Journal of pharmacy and pharmacology, 61(2), 251–256. https://doi.org/10.1211/jpp/61.02.0016.

Otto, M. W., Simon, N. M., Wisniewski, S. R., Miklowitz, D. J., Kogan, J. N., Reilly-Harrington, N. A., Frank, E., Nierenberg, A. A., Marangell, L. B., Sagduyu, K., Weiss, R. D., Miyahara, S., Thas, M. E., Sachs, G. S., Pollack, M. H., & STEP-BD Investigators. (2006). Prospective 12-month course of bipolar disorder in out-patients with and without comorbid anxiety disorders. The British journal of psychiatry: the journal of mental science, 189, 20–25. https://doi.org/10.1192/bjp.bp.104.007773.

Panijel, M. (1985) Therapy of symptoms of anxiety. Therapiewoche, 41, 4659–4668.

Papakostas, G. I. (2008). Tolerability of modern antidepressants. The Journal of clinical psychiatry, 69 Suppl. E1, 8–13.

Perlis, R. H., Ostacher, M. J., Miklowitz, D. J., Smoller, J. W., Dennehy, E. B., Cowperthwait, C., Nierenberg, A. A., Thase, M. E., & Sachs, G. S. (2010). Benzodiazepine use and risk of recurrence in bipolar disorder: a STEP-BD report. The Journal of clinical psychiatry, 71(2), 194–200. https://doi.org/10.4088/JCP.09m05019yel.

Perugi, G., Hantouche, E., & Vannucchi, G. (2017). Diagnosis and Treatment of Cyclothymia: The "Primacy" of Temperament. Current neuropharmacology, 15(3), 372–379. https://doi.org/10.2174/1570159X14666160616120157.

Petrie, G. N., Nastase, A. S., Aukema, R. J., & Hill, M. N. (2021). Endocannabinoids, cannabinoids and the regulation of anxiety. Neuropharmacology, 195, 108626. https://doi.org/10.1016/j.neuropharm.2021.108626.

Petrisor, G., Motelica, L., Craciun, L. N., Oprea, O. C., Ficai, D., & Ficai, A. (2022). Melissa officinalis: Composition, Pharmacological Effects and Derived Release Systems-A Review. International journal of molecular sciences, 23(7), 3591. https://doi.org/10.3390/ijms23073591.

Pittler, M. H., & Ernst, E. (2003). Kava extract for treating anxiety. The Cochrane database of systematic reviews, (1), CD003383. https://doi.org/10.1002/14651858.CD003383.

Porter, R., Ferrier, N., & Ashton, H. (1999) Anticonvulsants as mood stabilisers. Advances in Psychiatric Treatment, 5(22), 96–103. http://dx.doi.org/10.1192/apt.5.2.96.

Putnins, S. I., Griffin, M. L., Fitzmaurice, G. M., Dodd, D. R., & Weiss, R. D. (2012). Poor sleep at baseline predicts worse mood outcomes in patients with co-occurring bipolar disorder and substance dependence. The Journal of clinical psychiatry, 73(5), 703–708. https://doi.org/10.4088/JCP.11m07007.

Rahimi, R., Nikfar, S., & Abdollahi, M. (2009). Efficacy and tolerability of Hypericum perforatum in major depressive disorder in comparison with selective serotonin reuptake inhibitors: a meta-analysis. Progress in neuro-psychopharmacology & biological psychiatry, 33(1), 118–127. https://doi.org/10.1016/j.pnpbp.2008.10.018.

Rakofsky, J. J., & Dunlop, B. W. (2011). Treating nonspecific anxiety and anxiety disorders in patients with bipolar disorder: a review. The Journal of clinical psychiatry, 72(1), 81–90. https://doi.org/10.4088/JCP.09r05815gre.

Regier, D. A., Farmer, M. E., Rae, D. S., Locke, B. Z., Keith, S. J., Judd, L. L., & Goodwin, F. K. (1990). Comorbidity of mental disorders with alcohol and other drug abuse. Results from the Epidemiologic Catchment Area (ECA) Study. JAMA, 264(19), 2511–2518.

Rodríguez-Landa, J. F., German-Ponciano, L. J., Puga-Olguín, A., & Olmos-Vázquez, O. J. (2022). Pharmacological, Neurochemical, and Behavioral Mechanisms Underlying the Anxiolytic- and Antidepressant-like Effects of Flavonoid Chrysin. Molecules (Basel, Switzerland), 27(11), 3551. https://doi.org/10.3390/molecules27113551.

Romero-Sandoval, E. A., Kolano, A. L., & Alvarado-Vázquez, P. A. (2017). Cannabis and Cannabinoids for Chronic Pain. Current rheumatology reports, 19(11), 67. https://doi.org/10.1007/s11926-017-0693-1.

Sachs, G. S., Grossman, F., Ghaemi, S. N., Okamoto, A., & Bowden, C. L. (2002). Combination of a mood stabilizer with risperidone or haloperidol for treatment of acute mania: a double-blind, placebo-controlled comparison of efficacy and safety. The American journal of psychiatry, 159(7), 1146–1154. https://doi.org/10.1176/appi.ajp.159.7.1146.

Sachs, G. S., Printz, D. J., Kahn, D. A., Carpenter, D., & Docherty, J. P. (2000). The Expert Consensus Guideline Series: Medication Treatment of Bipolar Disorder 2000. Postgraduate medicine, Spec No, 1–104.

Sachs, G., Sanchez, R., Marcus, R., Stock, E., McQuade, R., Carson, W., Abou-Gharbia, N., Impellizzeri, C., Kaplita, S., Rollin, L., Iwamoto, T., & Aripiprazole Study Group. (2006). Aripiprazole in the treatment of acute manic or mixed episodes in patients with bipolar I disorder: a 3-week placebo-controlled study. Journal of psychopharmacology (Oxford, England), 20(4), 536–546. https://doi.org/10.1177/0269881106059693.

Sarris, J., & Kavanagh, D. J. (2009). Kava and St. John's Wort: current evidence for use in mood and anxiety disorders. Journal of alternative and complementary medicine (New York, N.Y.), 15(8), 827–836. https://doi.org/10.1089/acm.2009.0066.

Sarris, J., Panossian, A., Schweitzer, I., Stough, C., & Scholey, A. (2011). Herbal medicine for depression, anxiety and insomnia: a review of psychopharmacology and clinical evidence. European neuropsychopharmacology: the journal of the European College of Neuropsychopharmacology, 21(12), 841–860. https://doi.org/10.1016/j.euroneuro.2011.04.002.

Savage, K. M., Stough, C. K., Byrne, G. J., Scholey, A., Bousman, C., Murphy, J., Macdonald, P., Suo, C., Hughes, M., Thomas, S., Teschke, R., Xing, C., & Sarris, J. (2015). Kava for the treatment of generalised anxiety disorder (K-GAD): study protocol for a randomised controlled trial. Trials, 16, 493. https://doi.org/10.1186/s13063-015-0986-5.

Schulz, V. (2006). Safety of St. John's Wort extract compared to synthetic antidepressants. Phytomedicine: international journal of phytotherapy and phytopharmacology, 13(3), 199–204. https://doi.org/10.1016/j.phymed.2005.07.005.

Schulze, T. G. (2010). Genetic research into bipolar disorder: the need for a research framework that integrates sophisticated molecular biology and clinically informed phenotype characterization. The Psychiatric clinics of North America, 33(1), 67–82. https://doi.org/10.1016/j.psc.2009.10.005.

Scott, J. (1995) Cognitive therapy for clients with bipolar disorder: a case example. Cognitive and Behavioural Practice, 3, 1-23.

Scott, J. (2001). Cognitive therapy as an adjunct to medication in bipolar disorder. The British journal of psychiatry: the journal of mental science, 178(Suppl 41), S164–S168.

Searson, R., Mansell, W., Lowens, I., & Tai, S. (2012). Think Effectively About Mood Swings (TEAMS): a case series of cognitive-behavioural therapy for bipolar disorders. Journal of behavior therapy and experimental psychiatry, 43(2), 770–779. https://doi.org/10.1016/j.jbtep.2011.10.001.

Sekhon, S., & Gupta, V. (2022). Mood Disorder. In StatPearls. StatPearls Publishing.

Shakeri, A., Sahebkar, A., & Javadi, B. (2016). Melissa officinalis L. – A review of its traditional uses, phytochemistry and pharmacology. Journal of ethnopharmacology, 188, 204–228. https://doi.org/10.1016/j.jep.2016.05.010.

Sherwood Brown, E., Suppes, T., Adinoff, B., & Rajan Thomas, N. (2001). Drug abuse and bipolar disorder: comorbidity or misdiagnosis? Journal of affective disorders, 65(2), 105–115. https://doi.org/10.1016/s0165-0327(00)00169-5.

Shi, D. Q., Liu, J. J., Feng, Y. M., Zhou, Y., Liao, C. C., Liu, D., Li, R. T., & Li, H. M. (2023). Iridoids and sesquiterpenoids from Valeriana officinalis and their bioactivities. Phytochemistry, 205, 113478. https://doi.org/10.1016/j.phytochem.2022.113478.

Shorter, E. (2009). The history of lithium therapy. Bipolar disorders, 11 Suppl. 2(Suppl. 2), 4–9. https://doi.org/10.1111/j.1399-5618.2009.00706.x.

Sierpina, V. S., Wollschlaeger, B., & Blumenthal, M. (2003). Ginkgo biloba. American family physician, 68(5), 923–926.

Simon, N. M., Otto, M. W., Weiss, R. D., Bauer, M. S., Miyahara, S., Wisniewski, S. R., Thase, M. E., Kogan, J., Frank, E., Nierenberg, A. A., Calabrese, J. R., Sachs, G. S., Pollack, M. H., & STEP-BD Investigators. (2004). Pharmacotherapy for bipolar disorder and comorbid conditions: baseline data from STEP-BD. Journal of clinical psychopharmacology, 24(5), 512–520. https://doi.org/10.1097/01.jcp.0000138772.40515.70.

Solé, B., Jiménez, E., Torrent, C., Reinares, M., Bonnin, C. D. M., Torres, I., Varo, C., Grande, I., Valls, E., Salagre, E., Sanchez-Moreno, J., Martinez-Aran, A., Carvalho, A. F., & Vieta, E. (2017). Cognitive Impairment in Bipolar Disorder: Treatment and Prevention Strategies. The international journal of neuropsychopharmacology, 20(8), 670–680. https://doi.org/10.1093/ijnp/pyx032.

Sonne, S. C., Brady, K. T., & Morton, W. A. (1994). Substance abuse and bipolar affective disorder. The Journal of nervous and mental disease, 182(6), 349–352. https://doi.org/10.1097/00005053-199406000-00007.

Spinella, M., & Eaton, L. A. (2002). Hypomania induced by herbal and pharmaceutical psychotropic medicines following mild traumatic brain injury. Brain injury, 16(4), 359–367. https://doi.org/10.1080/02699050110103319.

Starchenko, G., Hrytsyk, A., Raal, A., & Koshovyi, О. (2020). Phytochemical Profile and Pharmacological Activities of Water and Hydroethanolic Dry Extracts of Calluna vulgaris (L.) Hull. Herb. Plants (Basel, Switzerland), 9(6), 751. https://doi.org/10.3390/plants9060751.

Taylor, L. H., & Kobak, K. A. (2000). An open-label trial of St. John's Wort (Hypericum perforatum) in obsessive-compulsive disorder. The Journal of clinical psychiatry, 61(8), 575–578. https://doi.org/10.4088/jcp.v61n0806.

Teschke, R., Sarris, J., & Schweitzer, I. (2012). Kava hepatotoxicity in traditional and modern use: the presumed Pacific kava paradox hypothesis revisited. British journal of clinical pharmacology, 73(2), 170–174. https://doi.org/10.1111/j.1365-2125.2011.04070.x.

Thase, M. E., Macfadden, W., Weisler, R. H., Chang, W., Paulsson, B., Khan, A., Calabrese, J. R., & BOLDER II Study Group. (2006). Efficacy of quetiapine monotherapy in bipolar I and II depression: a double-blind, placebo-controlled study (the BOLDER II study). Journal of clinical psychopharmacology, 26(6), 600–609. https://doi.org/10.1097/01.jcp.0000248603.76231.b7.

Thomsen, M., & Schmidt, M. (2021). Health policy versus kava (Piper methysticum): Anxiolytic efficacy may be instrumental in restoring the reputation of a major South Pacific crop. Journal of ethnopharmacology, 268, 113582. https://doi.org/10.1016/j.jep.2020.113582.

Tohen, M., Chengappa, K. N., Suppes, T., Zarate, C. A., Jr, Calabrese, J. R., Bowden, C. L., Sachs, G. S., Kupfer, D. J., Baker, R. W., Risser, R. C., Keeter, E. L., Feldman, P. D., Tollefson, G. D., & Breier, A. (2002). Efficacy of olanzapine in combination with valproate or lithium in the treatment of mania in patients partially nonresponsive to valproate or lithium monotherapy. Archives of general psychiatry, 59(1), 62–69. https://doi.org/10.1001/archpsyc.59.1.62.

Tohen, M., Goldberg, J. F., Gonzalez-Pinto Arrillaga, A. M., Azorin, J. M., Vieta, E., Hardy-Bayle, M. C., Lawson, W. B., Emsley, R. A., Zhang, F., Baker, R. W., Risser, R. C., Namjoshi, M. A., Evans, A. R., & Breier, A. (2003). A 12-week, double-blind comparison of olanzapine vs haloperidol in the treatment of acute mania. Archives of general psychiatry, 60(12), 1218–1226. https://doi.org/10.1001/archpsyc.60.12.1218.

Tohen, M., Jacobs, T. G., Grundy, S. L., McElroy, S. L., Banov, M. C., Janicak, P. G., Sanger, T., Risser, R., Zhang, F., Toma, V., Francis, J., Tollefson, G. D., & Breier, A. (2000). Efficacy of olanzapine in acute bipolar mania: a double-blind, placebo-controlled study. The Olanzipine HGGW Study Group. Archives of general psychiatry, 57(9), 841–849. https://doi.org/10.1001/archpsyc.57.9.841.

Tohen, M., Sanger, T. M., McElroy, S. L., Tollefson, G. D., Chengappa, K. N., Daniel, D. G., Petty, F., Centorrino, F., Wang, R., Grundy, S. L., Greaney, M. G., Jacobs, T. G., David, S. R., & Toma, V. (1999). Olanzapine versus placebo in the treatment of acute mania. Olanzapine HGEH Study Group. The American journal of psychiatry, 156(5), 702–709. https://doi.org/10.1176/ajp.156.5.702.

Tohen, M., Zhang, F., Taylor, C. C., Burns, P., Zarate, C., Sanger, T., & Tollefson, G. (2001). A meta-analysis of the use of typical antipsychotic agents in bipolar disorder. Journal of affective disorders, 65(1), 85–93. https://doi.org/10.1016/s0165-0327(00)00162-2.

Torres-Hernández, B. A., Del Valle-Mojica, L. M., & Ortíz, J. G. (2015). Valerenic acid and Valeriana officinalis extracts delay onset of Pentylenetetrazole (PTZ)-Induced seizures in adult Danio rerio (Zebrafish). BMC complementary and alternative medicine, 15, 228. https://doi.org/10.1186/s12906-015-0731-3.

Uzun, S., Kozumplik, O., Jakovljević, M., & Sedić, B. (2010). Side effects of treatment with benzodiazepines. Psychiatria Danubina, 22(1), 90–93.

Williamson, E. M. (2001). Synergy and other interactions in phytomedicines. Phytomedicine : international journal of phytotherapy and phytopharmacology, 8(5), 401–409. https://doi.org/10.1078/0944-7113-00060.

Winokur, G., Turvey, C., Akiskal, H., Coryell, W., Solomon, D., Leon, A., Mueller, T., Endicott, J., Maser, J., & Keller, M. (1998). Alcoholism and drug abuse in three groups – bipolar I, unipolars and their acquaintances. Journal of affective disorders, 50(2-3), 81–89. https://doi.org/10.1016/s0165-0327(98)00108-6.

Wolfman, C., Viola, H., Paladini, A., Dajas, F., & Medina, J. H. (1994). Possible anxiolytic effects of chrysin, a central benzodiazepine receptor ligand isolated from Passiflora coerulea. Pharmacology, biochemistry, and behavior, 47(1), 1–4. https://doi.org/10.1016/0091-3057(94)90103-1.

USE OF PHYTOTHERAPY IN THE TREATMENT OF MENTAL ILLNESSES ON THE EXAMPLE OF BIPOLAR DISORDER

Authors

DOI:

Keywords:

Abstract

Downloads

References

Downloads

Published

How to Cite

Issue

Section

License

Language